No Data
Jilin Aodong Pharmaceutical Group (000623.SZ): Yanji Pharmaceutical has obtained the pharmaceutical registration certificate for polyethylene glycol eye drops.
On March 21, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) recently announced that its holding subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd. (referred to as "Yanji Pharmaceutical"), received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration for the specification of Polyvinyl Alcohol Eye Drops: 1.4% (0.4ml: 5.6mg). The indications for Polyvinyl Alcohol Eye Drops include serving as a lubricant to prevent or treat symptoms of eye dryness, foreign body sensation, eye fatigue, and to improve dry eye symptoms.
Jilin Aodong Pharmaceutical Group (000623.SZ): Actively exploring the possibilities of optimizing drug screening, clinical trial design, and other aspects through AI technology.
On March 19, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) stated on the investor interaction platform that the company always pays close attention to the technological changes and market trends in the Medical health industry, and maintains a high level of interest in the application prospects of AI technology in pharmaceutical research and development, production management, and the health sector. Currently, the company has introduced information technology, digitalization, and intelligent technology in the entire pharmaceutical process management, achieving equipment interconnectivity, data sharing, and flexible manufacturing through smart factory construction, laying a foundation for further exploration of AI empowerment in the future. On the research and development side, the company continues to conduct research on classic formulas of Traditional Chinese Medicine, formula granules, and Innovative Drugs, and actively explores.
Jilin Aodong Pharmaceutical Group (000623.SZ) currently does not operate in any AI-related business.
On March 19, 2023, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) stated on the investor interaction platform that the company’s current main business does not involve AI-related operations. The company is actively paying attention to the industrial changes brought about by the deep integration of AI and Medical. The company focuses on the development of its Pharmaceutical main business, equipping key projects such as Traditional Chinese Medicine formula granules with Asia Vets Control Systems. The production equipment and key links have full network coverage, achieving informationization, digitalization, and intelligence in production quality control. The company aims to drive the entire Industry Chain upgrade with 'Intelligence + Industrialization', consolidating core competitiveness through technological innovation and fulfilling its mission of high-quality development.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Investors in Jilin Aodong Pharmaceutical Group (SZSE:000623) Have Seen Returns of 20% Over the Past Year
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
